Interestingly, a previous meta-analysis reported the efficacy and safety of PD-1/PD-L1 in the treatment of RM-NPC, and the results were similar to those in this study (ORR 25%, and DCR 60%) [35]. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.